IP Library › Granted Patent US 10,314,823
Granted Patent B2
US 10,314,823 · App. 15/756,366 · Granted Jun 11, 2019

Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds

Inventors: Anne-Catherine Blumstein (Allschwil, CH); Gaelle Mathieu (Allschwil, CH); Loïc Jacob (Allschwil, CH); Florence Masse (Allschwil, CH); Azely Mirre (Allschwil, CH); Philippe Panchaud (Allschwil, CH); Christine Schmitt (Allschwil, CH); Jean-Luc Specklin (Allschwil, CH); Jean-Philippe Surivet (Allschwil, CH)
Assignee: IDORSIA PHARMACEUTICALS LTD
A61K31/4188A61K31/397A61K31/4439A61P31/04C07D487/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,314,823
App. No.
15/756,366
Granted
Jun 11, 2019
Kind
B2
Abstract

The invention relates to antibacterial compounds of formula I wherein M is one of the groups M A , M B and M C represented below wherein R 1 , M A , M B and M C are as defined in the specification; and to salts thereof.

Claims (204)

1. A compound of formula I

wherein

M is one of the groups M A , M B and M C represented below

wherein

R 1A represents hydrogen or fluorine;

R 3A represents 3-fluoroazetidin-3-yl, 3-fluoro-1-methyl-azetidin-3-yl, 1-acetyl-3-hydroxyazetidin-3-yl, 3-fluoro-1-(oxetan-3-yl)azetidin-3-yl, (3-fluoroazetidin-1-yl)methyl, (3-hydroxyazetidin-1-yl)methyl, (5-(hydroxymethyl)-2-oxooxazolidin-3-yl)methyl, (4-hydroxy-3-fluoropiperidin-1-yl)methyl, (4-amino-3-fluoropiperidin-1-yl)methyl, (4-hydroxy-3,3-difluoropiperidin-1-yl)methyl, (4-amino-3,3-difluoropiperidin-1-yl)methyl, (6-amino-3-azabicyclo[3.1.0]hexan-3-yl)methyl, (2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl, 2-morpholino-1-hydroxyethyl, 2-(methylsulfonyl)ethoxy, (3-hydroxyazetidin-1-yl)carbonyloxymethyl, (4-hydroxypiperidin-1-yl)carbonyloxymethyl, (4-methylpiperazin-1-yl)carbonyloxymethyl, N-(2-hydroxyethyl)-N-(methyl)carbamoyloxymethyl, 1-hydroxy-2-[(2-methoxyethyl)(methyl)amino]ethyl, azetidin-3-yloxycarbonylaminomethyl or (N-methylazetidin-3-yl)oxycarbonylaminomethyl;

R 1B represents trans-2-(1,2-dihydroxyethyl)cycloprop-1-yl, 1-(methylamino)cydoprop-1-yl, 1-(dimethylamino)cycloprop-1-yl, 2-(dimethylaminomethyl)cycloprop-1-yl, 1-((3-hydroxyazetidinyl)-1-carbonyloxymethyl)cycloprop-1-yl, 2-(morpholinomethyl)cycloprop-1-yl, 1-((4-methylpiperazinyl)-1-carbonyloxymethyl)cycloprop-1-yl, 4-fluoropyrrolidin-2-yl, (2-oxooxazolidin-3-yl)methyl, 1-(3-hydroxyazetidine)-1-carbonyloxymethyl, (4-hydroxypiperidin-1-yl)carbonyloxymethyl, 1-(4-methylpiperazine)-1-carbonyloxymethyl or N-methylazetidin-3-yl)oxycarbonylaminomethyl, or R 1B represents a group Q, Q being one of the groups Q A , Q B and Q C represented below

wherein

X A1 represents H, methyl-d, methyl-d2, (C 1 -C 4 )alkyl, acetyl, ω-(C 2 -C 3 )haloalkyl, ω-hydroxy(C 2 -C 3 )alkyl, 2,3-dihydroxyprop-1-yl, 3-hydroxy-2-(hydroxymethyl)prop-1-yl, oxetan-3-yl, thietan-3-yl, 1,1-dioxidothietan-3-yl, (C 3 -C 6 )cycloalkyl, 3-hydroxycyclobut-1-yl, tetrahydropyran-4-yl or (C 3 -C 6 )cycloalkyl(C 1 -C 3 )alkyl, X A21 and X A22 each independently represent H, (C 1 -C 4 )alkyl, (C 1 -C 3 )haloalkyl or hydroxy(C 1 -C 3 )alkyl, and

X A3 represents H, (C 1 -C 3 )alkyl or halogen,

provided that if X A1 represents oxetan-3-yl, at least one of X A21 , X A22 and X A3 does not represent H;

X B1 represents H, (C 1 -C 4 )alkyl, ω-hydroxy(C 2 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl, oxetan-3-yl or tetrahydropyran-4-yl,

X B21 and X B22 each independently represent H, (C 1 -C 4 )alkyl, (C 1 -C 3 )haloalkyl or hydroxy(C 1 -C 3 )alkyl, and

X B4 represents H, halogen, hydroxy or (C 1 -C 3 )alkyl;

X C1 represents H, (C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl, ω-hydroxy(C 2 -C 3 )alkyl, oxetan-3-yl or tetrahydropyran-4-yl,

X C2 represents H, (C 1 -C 4 )alkyl, (C 1 -C 3 )haloalkyl or hydroxy(C 1 -C 3 )alkyl,

X C3 represents H, halogen, hydroxy, (C 1 -C 4 )alkyl, (C 1 -C 3 )haloalkyl, hydroxy(C 1 -C 3 )alkyl, and

X C4 represents H, (C 1 -C 3 )alkyl, halogen or hydroxy;

R 1C represents hydrogen or fluorine;

R 3C represents a group Q as defined before; and

R 1 represents H, PO 3 H 2 , SO 3 H, phosphonooxymethyl or the group L represented below

wherein R 2 represents (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, [di(C 1 -C 4 )alkylamino](C 1 -C 4 )alkyl, phosphonooxy(C 1 -C 4 )alkyl, phosphonooxymethoxy, 2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl, (2-(phosphonooxy)-phenyl)-(C 1 -C 4 )alkyl, 2-(2-(phosphonooxy)-phenyl)-ethyl, or [2-(phosphonooxy-(C 1 -C 4 )alkyl)-phenyl]-(C 1 -C 4 )alkyl;

or a salt thereof.

2. A compound of formula I according to claim 1 , which is a compound of formula I CEP

wherein

M is one of the groups M A and M B represented below

wherein

R 1A represents hydrogen or fluorine;

R 3A represents 3-fluoroazetidin-3-yl, 3-fluoro-1-methyl-azetidin-3-yl, 1-acetyl-3-hydroxyazetidin-3-yl, 3-fluoro-1-(oxetan-3-yl)azetidin-3-yl, (3-fluoroazetidin-1-yl)methyl, (3-hydroxyazetidin-1-yl)methyl, (5-(hydroxymethyl)-2-oxooxazolidin-3-yl)methyl, (4-hydroxy-3-fluoropiperidin-1-yl)methyl, (4-amino-3-fluoropiperidin-1-yl)methyl, (4-hydroxy-3,3-difluoropiperidin-1-yl)methyl, (4-amino-3,3-difluoropiperidin-1-yl)methyl, (6-amino-3-azabicyclo[3.1.0]hexan-3-yl)methyl, (2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl, 2-morpholino-1-hydroxyethyl, 2-(methylsulfonyl)ethoxy, (3-hydroxyazetidin-1-yl)carbonyloxymethyl, (4-hydroxypiperidin-1-yl)carbonyloxymethyl, (4-methylpiperazin-1-yl)carbonyloxymethyl, N-(2-hydroxyethyl)-N-(methyl)carbamoyloxymethyl, 1-hydroxy-2-[(2-methoxyethyl)(methyl)amino]ethyl, azetidin-3-yloxycarbonylaminomethyl or (N-methylazetidin-3-yl)oxycarbonylaminomethyl;

R 1B represents trans-2-(1,2-dihydroxyethyl)cycloprop-1-yl, 1-(methylamino)cydoprop-1-yl, 1-(dimethylamino)cycloprop-1-yl, 2-(dimethylaminomethyl)cycloprop-1-yl, 1-((3-hydroxyazetidinyl)-1-carbonyloxymethyl)cycloprop-1-yl, 2-(morpholinomethyl)cycloprop-1-yl, 1-((4-methylpiperazinyl)-1-carbonyloxymethyl)cycloprop-1-yl, 4-fluoropyrrolidin-2-yl, (2-oxooxazolidin-3-yl)methyl, 1-(3-hydroxyazetidine)-1-carbonyloxymethyl, (4-hydroxypiperidin-1-yl)carbonyloxymethyl, 1-(4-methylpiperazine)-1-carbonyloxymethyl or N-methylazetidin-3-yl)oxycarbonylaminomethyl, or R 1B represents a group Q, Q being one of the groups Q A and Q B represented below

wherein

X A1 represents H, methyl-d, methyl-d2, (C 1 -C 4 )alkyl, acetyl, ω-(C 2 -C 3 )haloalkyl, ω-hydroxy(C 2 -C 3 )alkyl, 2,3-dihydroxyprop-1-yl, 3-hydroxy-2-(hydroxymethyl)prop-1-yl, oxetan-3-yl, 1,1-dioxidothietan-3-yl, (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )cycloalkyl(C 1 -C 3 )alkyl,

X A21 and X A22 each represent H, and

X A3 represents H, (C 1 -C 3 )alkyl or halogen,

provided that if X A1 represents oxetan-3-yl, then X A3 does not represent H;

X B1 represents H, (C 1 -C 4 )alkyl or oxetan-3-yl,

X B21 and X B22 each represent H, and

X B4 represents H, halogen or hydroxy;

or a salt thereof.

3. A compound of formula I according to claim 1 , wherein M is the group M A ;

or a salt thereof.

4. A compound of formula I according to claim 3 , wherein M is the group M A wherein R 1A represents hydrogen or fluorine and R 3A represents 3-fluoro-1-methyl-azetidin-3-yl, 3-fluoro-1-(oxetan-3-yl)azetidin-3-yl, (3-fluoroazetidin-1-yl)methyl, (3-hydroxyazetidin-1-yl)methyl, (4-hydroxy-3-fluoropiperidin-1-yl)methyl, (4-hydroxy-3,3-difluoropiperidin-1-yl)methyl, (6-amino-3-azabicyclo[3.1.0]hexan-3-yl)methyl, (2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl, 2-(methylsulfonyl)ethoxy, (3-hydroxyazetidin-1-yl)carbonyloxymethyl, (4-methylpiperazin-1-yl)carbonyloxymethyl, N-(2-hydroxyethyl)-N-(methyl)carbamoyloxymethyl or azetidin-3-yloxycarbonylaminomethyl;

or a salt thereof.

5. A compound of formula I according to claim 1 , wherein M is the group M B ;

or a salt thereof.

6. A compound of formula I according to claim 5 , wherein M is the group M B and R 1B represents trans-2-(1,2-dihydroxyethyl)cycloprop-1-yl, 1-(methylamino)cydoprop-1-yl, 1-(dimethylamino)cycloprop-1-yl, 2-(morpholinomethyl)cycloprop-1-yl or 1-(3-hydroxyazetidine)-1-carbonyloxymethyl;

or a salt thereof.

7. A compound of formula I according to claim 5 , wherein M is the group M B wherein R 1B represents the group Q A wherein X A1 represents H, methyl-d, methyl-d2, (C 1 -C 4 )alkyl, ω-(C 2 -C 3 )haloalkyl, ω-hydroxy(C 2 -C 3 )alkyl, (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )cycloalkyl(C 1 -C 3 )alkyl, X A21 and X A22 each represent H, and X A3 represents H, (C 1 -C 3 )alkyl or fluorine;

or a salt thereof.

8. A compound of formula I according to claim 7 , wherein M is the group M B wherein R 1B represents the group Q A wherein X A1 represents methyl, methyl-d, methyl-d2, 2-fluoro-ethyl, 2-hydroxy-ethyl, cycloprop-1-yl, 3-hydroxy-prop-1-yl or 3-hydroxycyclobut-1-yl, X A21 and X A22 each represent H, and X A3 represents H or fluorine;

or a salt thereof.

9. A compound of formula I according to claim 5 , wherein M is the group M B wherein R 1B represents the group Q A wherein X A1 represents cycloprop-1-yl, 3-hydroxycyclobut-1-yl or cyclohex-1-yl, X A21 and X A22 each represent H, and X A3 represents H;

or a salt thereof.

10. A compound of formula I according to claim 5 , wherein M is the group M B wherein R 1B represents the group Q A wherein X A1 represents methyl or ethyl,

one of X A21 and X A22 represents methyl or fluoromethyl and the other represents H, and X A3 represents H;

or a salt thereof.

11. A compound of formula I according to claim 5 , wherein M is the group M B wherein R 1B represents the group Q B wherein X B1 represents H or methyl, X B21 and X B22 each represent H, and X B4 represents H or fluorine;

or a salt thereof.

12. A compound of formula I according to claim 1 , which is selected from the following:

(2R)—N-hydroxy-4-(6-((4-((1R)-1-hydroxy-2-morpholinoethyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((4-((1S)-1-hydroxy-2-morpholinoethyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-((6-amino-3-azabicyclo[3.1.0]hexan-3-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(3R)-4-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)ethynyl)benzyl 4-hydroxypiperidine-1-carboxylate;

(2R)-4-(6-((4-(1-acetyl-3-hydroxyazetidin-3-yl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((1R,2R)-2-((S)-1,2-dihydroxyethyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(3R)-5-(2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)penta-2,4-diyn-1-yl 4-hydroxypiperidine-1-carboxylate;

(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(3-oxo-6-(5-(2-oxooxazolidin-3-yl)penta-1,3-diyn-1-yl)-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butanamide;

(3R)-4-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)ethynyl)benzyl 3-hydroxyazetidine-1-carboxylate;

(3R)-4-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)ethynyl)benzyl (2-hydroxyethyl)(methyl)carbamate;

(2R)—N-hydroxy-4-(6-((4-((5-(hydroxymethyl)-2-oxooxazolidin-3-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-(((3S*,4S*)-4-amino-3-fluoropiperidin-1-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-((4-amino-3,3-difluoropiperidin-1-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-(3-fluoroazetidin-3-yl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-(3-fluoro-1-(oxetan-3-yl)azetidin-3-yl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(3R)-4-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)ethynyl)benzyl 4-methylpiperazine-1-carboxylate;

(2R)-4-(6-((3-fluoroazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((3-fluoro-1-(oxetan-3-yl) azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-(3-fluoro-1-methylazetidin-3-yl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-(dimethylamino)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(3R)-(1-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)buta-1,3-diyn-1-yl)cyclopropyl)methyl 3-hydroxyazetidine-1-carboxylate;

(3R)-(1-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)buta-1,3-diyn-1-yl)cyclopropyl)methyl 4-methylpiperazine-1-carboxylate;

(3R)-5-(2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)penta-2,4-diyn-1-yl 3-hydroxyazetidine-1-carboxylate;

(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(6-((4-(2-(methylsulfonyl)ethoxy)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2 (3H)-yl)butanamide;

azetidin-3-yl (3R)-(4-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)ethynyl)benzyl)carbamate;

1-methylazetidin-3-yl (3R)-(4-((2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)ethynyl)benzyl)carbamate;

(2R)—N-hydroxy-4-(6-((4-(1-hydroxy-2-((2-methoxyethyl)(methyl)amino)ethyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(6-(((1R,2R)-2-(morpholinomethyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-((1-methylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(azetidin-3-ylbuta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2 (3H)-yl)-2-methyl-2-(methylsulfonyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)butanamide;

(2R)-4-(6-((1-acetylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((3-fluoro-1-methylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-((1-methylpiperidin-4-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(6-((1-(oxetan-3-yl)piperidin-4-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butanamide;

(2R)-4-(6-((4-(((3S*,4S*)-3-fluoro-4-hydroxypiperidin-1-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-(((S)-3,3-difluoro-4-hydroxypiperidin-1-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-((1-(methylamino)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

1-methylazetidin-3-yl (3R)-(5-(2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)penta-2,4-diyn-1-yl)carbamate;

(2R)—N-hydroxy-4-(6-(5-(4-hydroxypiperidin-1-yl)penta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-(((3R*,4S*)-3-fluoro-4-hydroxypiperidin-1-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((4-((3-hydroxyazetidin-1-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((1R,2R)-2-((dimethylamino)methyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((4-hydroxy-1-(oxetan-3-yl)piperidin-4-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-fluoro-1-methylpiperidin-4-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-fluoro-1-(oxetan-3-yl)piperidin-4-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((4-hydroxy-1-methylpiperidin-4-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((4-((3-fluoro azetidin-1-yl)methyl)phenyl)ethynyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(3R)-5-(2-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-3-oxo-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-6-yl)penta-2,4-diyn-1-yl 4-methylpiperazine-1-carboxylate;

(2R)-4-(6-((1-((R)-2,3-dihydroxypropyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-((1-(methyl-d2)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((2S,4S)-4-fluoropyrrolidin-2-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-ethylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2 (3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-(cyclopropylmethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((1S,2S)-2-((R)-1,2-dihydroxyethyl)cyclopropyl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-cyclopropylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(3-oxo-6-((1-(2,2,2-trifluoroethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butanamide;

(2R)-4-(6-((1-isopropylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl-2-methyl-2-(methylsulfonyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-((1-(methyl-d)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-(2-fluoroethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-cyclobutylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-(1,1-dioxidothietan-3-yl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((1-(3-hydroxypropyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1,3-dimethylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((3-fluoro-1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((1-(3-hydroxy-2-(hydroxymethyl)propyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-(2,2-difluoroethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; and

(2R)—N-hydroxy-4-(6-((1-(3-hydroxycyclobutyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

or a salt thereof.

13. A compound of formula I according to claim 1 , which is selected from the following:

(2R)-4-(6-((1-cyclohexylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((3R)-3-fluoro-1-methylpyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((3S)-3-fluoro-1-methylpyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-cyclopentylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(3-oxo-6-((1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)buta-1,3-diyn-1-yl)-1H-pyrrolo[1,2-c]imidazol-2 (3H)-yl)butanamide;

(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(3-oxo-6-((1-(thietan-3-yl)azetidin-3-yl)buta-1,3-diyn-1-yl)-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butanamide;

(2R)-4-(6-((1-cyclopropyl-3-fluoropyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((3-fluoro-1-(2-hydroxyethyl)pyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((3-fluoropyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((3-ethyl-1-methylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1,3-dimethylpyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-((1-methylpyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(2-fluoro-4-((1-methylazetidin-3-yl)ethynyl)phenyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-(4-((1-methylazetidin-3-yl)ethynyl)phenyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

(2R)-2-(3-((4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamido)oxy)-3-oxopropyl)phenyl dihydrogen phosphate;

(2R)-4-(6-(2-fluoro-4-((1-methylpiperidin-4-yl)ethynyl)phenyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(2-fluoro-4-((1-(2-hydroxyethyl)azetidin-3-yl)ethynyl)phenyl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(6-((1-(oxetan-3-yl)pyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butanamide;

(2R)—N-hydroxy-4-(6-((1-((1r,3r)-3-hydroxycyclobutyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((1-((1s,3s)-3-hydroxycyclobutyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((2S,3R)-1,2-dimethylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((2R,3S)-1,2-dimethylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-(((3R,5R)-5-(hydroxymethyl)-1-methylpyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-(((2R,3R)-2-(hydroxymethyl)-1-methylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(6-(((2R,3R)-1,2-dimethylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-(((2S,3S)-2-(hydroxymethyl)-1-methylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-(((2S,3S)-2-(fluoromethyl)-1-methylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-(((3S*,4R*)-4-hydroxy-1-methylpyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide; and

(2R)—N-hydroxy-4-(6-(((3R,5R)-5-(hydroxymethyl)-1-(oxetan-3-yl)pyrrolidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

or a salt thereof.

14. A pharmaceutical composition containing, as active principle, a compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

15. A compound of formula I according to claim 5 , wherein M is the group M B , wherein R 1B represents the group Q A , wherein X A1 represents methyl, methyl-d, methyl-d2, 2-fluoro-ethyl, 2-hydroxy-ethyl, cycloprop-1-yl, 3-hydroxy-prop-1-yl or 3-hydroxycyclobut-1-yl; X A21 and X A22 each represent H; and X A3 represents H;

or a salt thereof.

16. A compound of formula I according to claim 1 , wherein R 1 represents (2-(phosphonooxy)-phenyl)-(C 1 -C 4 )alkyl;

or a salt thereof.

17. A compound of formula I according to claim 1 , wherein R 1 represents H; or a salt thereof.

18. A compound of formula I according to claim 5 , wherein R 1 represents (2-(phosphonooxy)-phenyl)-(C 1 -C 4 )alkyl;

or a salt thereof.

19. A compound of formula I according to claim 5 , wherein R 1 represents H;

or a salt thereof.

20. A compound of formula I according to claim 15 , wherein R 1 represents (2-(phosphonooxy)-phenyl)-(C 1 -C 4 )alkyl;

or a salt thereof.

21. A compound of formula I according to claim 15 , wherein R 1 represents H;

or a salt thereof.

22. A compound of formula I according to claim 15 , which is selected from the following:

(2R)—N-hydroxy-2-methyl-4-(6-((1-methylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-((1-(methyl-d2)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-cyclopropylazetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-2-methyl-4-(6-((1-(methyl-d)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-(methylsulfonyl)butanamide;

(2R)-4-(6-((1-(2-fluoroethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((1-(3-hydroxypropyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(2R)—N-hydroxy-4-(6-((1-(3-hydroxycyclobutyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide; and

(2R)-2-(3-((4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamido)oxy)-3-oxopropyl)phenyl dihydrogen phosphate;

or a salt thereof.

23. The compound of formula I according to claim 22 , which is (2R)—N-hydroxy-4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

or a salt thereof.

24. The compound of formula I according to claim 22 , which is (2R)-2-(3-((4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamido)oxy)-3-oxopropyl)phenyl dihydrogen phosphate;

or a salt thereof.

25. A pharmaceutical composition containing, as active principle, a compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

26. A pharmaceutical composition containing, as active principle, the compound defined in claim 23 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

27. A pharmaceutical composition containing, as active principle, the compound defined in claim 24 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

28. A method of treatment of a bacterial infection, comprising administering to a subject in need thereof a compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof.

29. A method of treatment of a bacterial infection, comprising administering to a subject in need thereof the compound defined in claim 23 , or a pharmaceutically acceptable salt thereof.

30. A method of treatment of a bacterial infection, comprising administering to a subject in need thereof the compound defined in claim 24 , or a pharmaceutically acceptable salt thereof.

31. A method of treatment of a bacterial infection, comprising administering to a subject in need thereof the pharmaceutical composition defined in claim 26 .

32. A method of treatment of a bacterial infection, comprising administering to a subject in need thereof the pharmaceutical composition defined in claim 27 .

33. The method according to claim 28 , wherein the bacterial infection is a Gram-negative bacterial infection.

34. The method according to claim 29 , wherein the bacterial infection is a Gram-negative bacterial infection.

35. The method according to claim 30 , wherein the bacterial infection is a Gram-negative bacterial infection.

36. The method according to claim 31 , wherein the bacterial infection is a Gram-negative bacterial infection.

37. The method according to claim 32 , wherein the bacterial infection is a Gram-negative bacterial infection.

38. A pharmaceutical composition comprising (2R)—N-hydroxy-4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamide, or a salt thereof.

39. A pharmaceutical composition comprising (2R)-2-(3-((4-(6-((1-(2-hydroxyethyl)azetidin-3-yl)buta-1,3-diyn-1-yl)-3-oxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)-2-methyl-2-(methylsulfonyl)butanamido)oxy)-3-oxopropyl)phenyl dihydrogen phosphate, or a salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: BLUMSTEIN, ANNE-CATHERINE; MATHIEU, GAELLE; JACOB, LOÏC; MASSE, FLORENCE; MIRRE, AZELY; PANCHAUD, PHILIPPE; SCHMITT, CHRISTINE; SURIVET, JEAN-PHILIPPE
To: ACTELION PHARMACEUTICALS LTD
Reel/Frame 045067/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 045067/0520 →
Priority Claims (1)
WO PCT/EP2015/070144 · Sep 3, 2015 · international
Continuity (1)
Related Publication 20180250273A1 · Sep 6, 2018
Cited By (1)
US 12,577,208